# Twice-Yearly Eczema Shots Maintain 85% Clearance, Data Show - Date: 2026-03-23 - Category: Biotech & Life Sciences Two Injections a Year: Apogee's Eczema Drug Posts Durability Data That Could Reshape the Dupixent Era Apogee Therapeutics released 52-week maintenance data for zumilokibart, its anti-IL-13 antibody for moderate-to-severe atopic dermatitis. ---